Search Results - "Harmatz, Jerold S."

Refine Results
  1. 1

    Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration by Greenblatt, David J., Harmatz, Jerold S., Singh, Nikhilesh N., Steinberg, Frank, Roth, Thomas, Moline, Margaret L., Harris, Stephen C., Kapil, Ram P.

    Published in Journal of clinical pharmacology (01-03-2014)
    “…The effect of dose and gender on the pharmacokinetics (PK) and pharmacodynamics (PD) of zolpidem after administration of a buffered zolpidem sublingual tablet…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Mechanism of cytochrome P450-3A inhibition by ketoconazole by Greenblatt, David J., Zhao, Yanli, Venkatakrishnan, Karthik, Duan, Su X., Harmatz, Jerold S., Parent, Sarah J., Court, Michael H., von Moltke, Lisa L.

    Published in Journal of pharmacy and pharmacology (01-02-2011)
    “…Objectives  Ketoconazole is extensively used as an index inhibitor of cytochrome P450‐3A (CYP3A) activity in vitro and in vivo, but the mechanism of…”
    Get full text
    Journal Article
  4. 4

    Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen by Zhao, Yanli, Harmatz, Jerold S., Epstein, Carol R., Nakagawa, Yukako, Kurosaki, Chie, Nakamura, Tetsuro, Kadota, Takumi, Giesing, Dennis, Court, Michael H., Greenblatt, David J.

    Published in British journal of clinical pharmacology (01-11-2015)
    “…Aims The antiviral agent favipiravir is likely to be co‐prescribed with acetaminophen (paracetamol). The present study evaluated the possiblility of a…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion by He, Xi, Hesse, Leah M., Hazarika, Suwagmani, Masse, Gina, Harmatz, Jerold S., Greenblatt, David J., Court, Michael H.

    Published in British journal of clinical pharmacology (01-11-2009)
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • UDP‐glucuronosyltransferase (UGT) 2B15 is a major drug glucuronidation enzyme expressed in human liver. • Oxazepam…”
    Get full text
    Journal Article
  7. 7

    Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily by Reddy, Patrick, Ellington, David, Zhu, Yiliang, Zdrojewski, Immo, Parent, Sarah J., Harmatz, Jerold S., Derendorf, Hartmut, Greenblatt, David J., Browne, Jr, Kevin

    Published in British journal of clinical pharmacology (01-09-2011)
    “…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In previous studies of healthy volunteers, administration of atorvastatin with very large quantities of grapefruit…”
    Get full text
    Journal Article
  8. 8

    Zolpidem and Gender: Are Women Really At Risk? by Greenblatt, David J, Harmatz, Jerold S, Roth, Thomas

    Published in Journal of clinical psychopharmacology (01-05-2019)
    “…In 2013 the Food and Drug Administration (FDA) claimed the existence of new data showing women to be at risk for excessive daytime sedation and impaired…”
    Get full text
    Journal Article
  9. 9

    Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450‐3A in drug–drug interaction studies by Greenblatt, David J., Harmatz, Jerold S.

    Published in British journal of clinical pharmacology (01-09-2015)
    “…Aims The regulatory prohibition of ketoconazole as a CYP3A index inhibitor in drug–drug interaction (DDI) studies has compelled consideration of alternative…”
    Get full text
    Journal Article
  10. 10

    Inhibition of human cytochromes P450 by components of Ginkgo biloba by von Moltke, Lisa L., Weemhoff, James L., Bedir, Erdal, Khan, Ikhlas A., Harmatz, Jerold S., Goldman, Peter, Greenblatt, David J.

    Published in Journal of pharmacy and pharmacology (01-08-2004)
    “…The extraction, isolation and characterization of 29 natural products contained in Ginkgo biloba have been described, which we have now tested for their…”
    Get full text
    Journal Article
  11. 11

    Effect of lipophilicity on drug distribution and elimination: Influence of obesity by Bruno, Christopher D., Harmatz, Jerold S., Duan, Su X., Zhang, Qingchen, Chow, Christina R., Greenblatt, David J.

    Published in British journal of clinical pharmacology (01-08-2021)
    “…Aims For a given passively‐distributed lipophilic drug, the extent of in vivo distribution (pharmacokinetic volume of distribution, Vd) in obese individuals…”
    Get full text
    Journal Article
  12. 12

    Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy by Greenblatt, David J., Bruno, Christopher D., Harmatz, Jerold S., Zhang, Qingchen, Chow, Christina R.

    Published in Journal of clinical pharmacology (01-11-2022)
    “…In 1979, the late Dr. Darrell R. Abernethy and colleagues began a series of clinical studies aimed at understanding the pertinent determinants of drug…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Clinical Consequences of Altered Drug Disposition in Obesity: Call for Change by Bruno, Christopher D., Greenblatt, David J., Harmatz, Jerold S., Chow, Christina R.

    Published in Journal of clinical pharmacology (01-11-2023)
    “…Abstract Obesity is a serious condition with many known comorbid conditions and other health risks. Despite the rising global rates of obesity, drug…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men by Olubodun, Joel O., Ochs, Hermann R., Von Moltke, Lisa L., Roubenoff, Ronenn, Hesse, Leah M., Harmatz, Jerold S., Shader, Richard I., Greenblatt, David J.

    Published in British journal of clinical pharmacology (01-09-2003)
    “…Aims  The influence of ageing on the pharmacokinetics of zolpidem, an extensively prescribed hypnotic medication, was evaluated in healthy human volunteers…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety by Greenblatt, David J, Harmatz, Jerold S, Chow, Christina R

    Published in Journal of clinical psychopharmacology (01-06-2018)
    “…Obesity and depression are common comorbid conditions. The objective of the study was to evaluate the effect of obesity on the pharmacokinetics of the…”
    Get full text
    Journal Article
  20. 20

    Fluvoxamine impairs single‐dose caffeine clearance without altering caffeine pharmacodynamics by Culm‐Merdek, Kerry E., Von Moltke, Lisa L., Harmatz, Jerold S., Greenblatt, David J.

    Published in British journal of clinical pharmacology (01-11-2005)
    “…Background Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half‐life, which is attributable to inhibition of…”
    Get full text
    Journal Article